

12th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

“Recent Advances and New Directions in Cancer Therapy”



August 12-14, 2016
The Westin Pasadena
Pasadena, CA

Presented by the California Cancer Consortium

University of California Davis Comprehensive Cancer Center
SACRAMENTO, CA

City of Hope Comprehensive Cancer Center
DUARTE, CA

University of Southern California/Norris Comprehensive Cancer Center
LOS ANGELES, CA

Stanford Cancer Institute
STANFORD, CA

Conference Chairs:

**Primo Lara, Jr., M.D. | Edward Newman, Ph.D.
Robert Morgan, M.D.**

Educational Steering Committee:

David Gandara, M.D.

Shivaani Kummar, M.D.

Heinz-Josef Lenz, M.D.

Sponsored by:
THE MEDICAL EDUCATOR
CONSORTIUM



PROGRAM CHAIRS

Primo Lara, Jr., M.D.

Professor of Medicine
University of California Davis School of
Medicine
Associate Director for Translational Research
University of California Davis
Comprehensive Cancer Center

Edward Newman, Ph.D.

Associate Professor, Cancer Biology
Co-Leader of the Development Cancer
Therapeutics Program
Core Facility
City of Hope Comprehensive Cancer Center
Duarte, CA

Robert Morgan, M.D.

Professor of Medicine
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center
Duarte, CA

STEERING COMMITTEE

David R. Gandara, M.D.

Professor of Medicine
University of California Davis School
of Medicine
Senior Advisor to the Director, University
of California Davis Comprehensive
Cancer Center

Shivaani Kummar, M.D.

Professor of Medicine
Stanford University School of Medicine

Heinz-Josef Lenz, M.D.

Professor of Medicine and Preventive
Medicine, Section Head of GI Oncology
University of Southern California,
Keck School of Medicine
Associate Director for Clinical Research,
University of Southern California Norris
Comprehensive Cancer Center

Christine Brown, Ph.D.

Associate Research Professor
City of Hope Comprehensive Cancer Center

Helen Chew, M.D.

Professor of Medicine
University of California Davis School
of Medicine

Warren Chow, M.D.

Clinical Professor
City of Hope Comprehensive Cancer Center

Vincent Chung, M.D.

Assistant Professor, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

A. Dimitrios Colevas, M.D.

Associate Professor of Medicine
Stanford University School of Medicine

Mihaela Cristea, M.D.

Associate Clinical Professor, Department of
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

Tanya Dorff, M.D.

Assistant Professor
University of Southern California Keck
School of Medicine
Norris Comprehensive Cancer Center

Oliver Dorigo, M.D., Ph.D.

Professor
Stanford University School of Medicine

Anthony El-Khoueiry, M.D.

Associate Professor
University of Southern California Keck
School of Medicine
Norris Comprehensive Cancer Center

Paul Frankel, Ph.D.

Staff Scientist, Division of Biostatistics,
Department of Information Sciences
Beckman Research Institute, City of Hope
Comprehensive Cancer Center

David R. Gandara, M.D.

Professor of Medicine, University of California
Davis School of Medicine
Senior Advisor to the Director, University
of California Davis Comprehensive Cancer
Center

Barbara Gitlitz, M.D.

Associate Professor of Medicine, Keck School
of Medicine
University of Southern California,
Norris Comprehensive Cancer Center

Susan Groshen, Ph.D.

Professor of Medicine and Director,
Biostatistics Core
University of Southern California,
Norris Comprehensive Cancer Center

Alex Herrera, M.D.

Assistant Professor, Department of
Hematology and Hematopoietic Cell
Transplantation
City of Hope Comprehensive Cancer Center

James Hu, M.D.

Assistant Professor of Medicine, Keck School
of Medicine
University of Southern California,
Norris Comprehensive Cancer Center

Brian Jonas, M.D., Ph.D.

Assistant Professor, Division of Hematology/
Oncology, University of California Davis
School of Medicine

Kevin Kelly, M.D., Ph.D.

Associate Professor
University of Southern California, Keck
School of Medicine

Marianna Koczywas, M.D.

Clinical Professor of Medicine
City of Hope Comprehensive Cancer Center

Shivaani Kummar, M.D.

Professor of Medicine
Stanford University School of Medicine

Heinz-Josef Lenz, M.D.

Professor of Medicine and Preventive
Medicine, Section Head of GI Oncology
University of Southern California, Keck
School of Medicine
Associate Director for Clinical Research
University Southern California Norris
Comprehensive Cancer Center

DISTINGUISHED FACULTY

Mehrdad Abedi, M.D.

Professor of Medicine
University of California Davis School of
Medicine

Primo N. Lara, Jr., M.D.

Professor of Medicine
University of California Davis School of
Medicine
Associate Director for Translational Research,
University of California Davis Comprehensive
Cancer Center

Tianhong Li, M.D., Ph.D.

Associate Professor, University of California
Davis School of Medicine
University of California Davis Comprehensive
Cancer Center

Jeffery Longmate, Ph.D.

Professor and Director, Division of
Biostatistics, Department of Information
Sciences
Beckman Research Institute,
City of Hope Comprehensive Cancer Center

Philip Mack, Ph.D.

Professor of Medicine, University of California
Davis School of Medicine
Director, Cancer Molecular Pharmacology,
University of California Davis Comprehensive
Cancer Center

Guido Marcucci, M.D.

Professor of Medicine, Department of
Hematology and Hematopoietic Cell
Transplantation
City of Hope Comprehensive Cancer Center

Kim Margolin, M.D.

Professor of Medicine, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

Emanuel Maverakis M.D.

Associate Professor
Department of Dermatology and Medical
Microbiology and Immunology
University of California, Davis

Robert Morgan, M.D.

Professor of Medicine, Department of Medical
Oncology and Therapeutics Research
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center

Edward Newman, Ph.D.

Associate Professor, Cancer Biology
Co-Leader, Developmental Cancer
Therapeutics Program
City of Hope Comprehensive Cancer Center

David Quinn, MBBS, Ph.D.

Associate Professor and Head, Section of
GU Medical Oncology, USC Keck School of
Medicine
Leader, Developmental Therapeutics Program,
University of Southern California Norris
Comprehensive Cancer Center

Jonathan Riess, M.D., MS

Assistant Professor
University of California Davis School of
Medicine

Aaron Rosenberg, M.D., MS

Assistant Professor
University of California Davis School
of Medicine

Sarmad Sadeghi, M.D.

Assistant Professor
University of Southern California, Keck
School of Medicine

Ravi Salgia, M.D., Ph.D.

Professor and Chair, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

Tanya Siddiqi, M.D.

Assistant Clinical Professor, Department of
Hematology
Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center

George Sledge, M.D.

Professor of Medicine and Chief, Division of
Oncology
Stanford University School of Medicine

Sandya Srinivas, M.D.

Associate Professor
Stanford University School of Medicine

Timothy Synold, Pharm.D.

Director, Analytical Pharmacology Core
Facility; Professor, Cancer Biology
City of Hope Comprehensive Cancer Center

Joseph Tuscano, M.D.

Professor of Medicine, Division of Hematology
and Oncology, UC Davis School of Medicine
University of California Davis Comprehensive
Cancer Center

Przemyslaw Twardowski, M.D.

Associate Professor, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

“Recent Advances and New Directions in Cancer Therapy”

COURSE DESCRIPTION

This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVES

After participating in this educational activity, you should be able to:

- Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of various tumor types, and identify specific opportunities for therapeutic intervention.
- Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of patients with cancer.
- Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of patients with cancer.
- Discuss new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCE

This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENT

This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps

identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently, improve patient outcomes.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Educator Consortium designates this educational activity for a maximum of 15 *AMA PRA Category 1 Credit(s)*TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial Relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational Activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is *AMA PRA Category 1 Credits*TM, and has been taken within the appropriate time frames.

CONFERENCE AGENDA

12th Annual California Cancer Consortium Conference “Recent Advances and New Directions in Cancer Therapy”

FRIDAY, AUGUST 12th, 2016

1:30 - 3:00 pm	Registration & Visit Exhibits
1:30 - 2:30 pm	CCC Business Meeting (by invitation only)
3:00 pm	Welcome and Introductions
3:05 pm	Pre-session Survey/MOC Pre-Questionnaire

Session 1: Inhibition of Signal Transduction and Angiogenesis Pathways *Chairs: Primo Lara (UC Davis) and Edward Newman (City of Hope)*

3:15 pm	EGFR Inhibitors: State of the Art <i>Marianna Koczywas, City of Hope</i>
3:35 pm	Question-and-Answer Session
3:40 pm	MET Pathway Inhibitors <i>Ravi Salgia, City of Hope</i>
4:00 pm	Question-and-Answer Session
4:05 pm	FGF and FGFR as Therapeutic Targets <i>Philip C. Mack, UC Davis</i>
4:25 pm	Question-and-Answer Session
4:30 pm	Angiogenesis Inhibitors <i>Oliver Dorigo, Stanford</i>
4:50 pm	Question-and-Answer Session
4:55 pm	EphB4 Inhibitors <i>Barbara Gitlitz, USC</i>
5:15 pm	Question-and-Answer Session
5:20 pm	Refreshment Break & Visit Exhibits

Session 2: Clinical Trial Design *Chairs: Susan Groshen (USC) and Paul Frankel (City of Hope)*

5:35 pm	Phase I Designs: Is the Answer You Get the One You Want? <i>Paul Frankel, City of Hope</i>
5:50 pm	Question-and-Answer Session
5:55 pm	How to Select the Right Phase 2 Endpoints <i>Susan Groshen, USC</i>
6:10 pm	Question-and-Answer Session
6:15 pm	Phase Ib Trials with Expansion Cohorts and Phase 2 Trials: a Case for Seamless Study Design <i>Jeff Longmate, City of Hope</i>
6:30 pm	Question-and-Answer Session
6:35 pm	Roundtable Discussion: Statistical Considerations in the ET-CTN era <i>Moderator: Edward Newman (City of Hope)</i> <i>Participants: Jeff Longmate, Paul Frankel, Susan Groshen, David Gandara</i>
6:55 pm	Post-session Survey
7:00 - 8:00 pm	Wine and Cheese Welcome Reception & Visit Exhibits

CONFERENCE AGENDA

SATURDAY, AUGUST 13th, 2016

7:30 am	Registration, Refreshments & Visit Exhibits
8:00 – 8:45 am	Breakfast & Learn Symposia (non CME)
9:00 am	Introduction
9:05 am	Pre-session Survey

Session 3: Cancer Immunotherapy

Chairs: Tianhong Li (UC Davis) and Primo Lara (UC Davis)

9:10 am	Immunology for Dummies: A Review <i>Kim Margolin, City of Hope</i>
9:30 am	Question-and-Answer Session
9:35 am	Checkpoint inhibitor therapy <i>Primo Lara, UC Davis</i>
9:55 am	Question-and-Answer Session
10:00 am	Cell Based Immunotherapy Approaches <i>Christine Brown, City of Hope</i>
10:20 am	Question and Answer
10:25 am	Cancer Vaccines <i>Vincent Chung, City of Hope</i>
10:45 am	Question and Answer

Session 4: Lung Cancer

Chairs: Marianna Koczywas (City of Hope) and Jonathan Riess (UC Davis)

10:50 am	Non-Small Cell Lung Cancer as a Model for Biomarker Driven and Personalized Therapy <i>David Gandara, UC Davis</i>
11:10 am	Question-and-Answer Session
11:15 am	Small Cell Lung Cancer and Thymoma: What's New? <i>Jonathan Riess, UC Davis</i>
11:35 am	Question-and-Answer Session
11:40 am	Close Morning Session
11:50 – 12:50 pm	Lunch & Learn Symposia (non cme)
12:50 – 1:05 pm	Refreshments & Visit Exhibits

Session 5: Gastrointestinal Malignancies

Chairs: Robert Morgan (City of Hope)

1:05 pm	Systemic Therapy for Colorectal Carcinoma in the Adjuvant and Metastatic Settings <i>Heinz-Josef Lenz, USC</i>
1:25 pm	Question-and-Answer Session
1:30 pm	New Developments in Esophagogastric and Pancreatic Cancers <i>Anthony El-Khoueiri, USC</i>
1:50 pm	Question-and-Answer Session

CONFERENCE AGENDA

Session 6: Hematologic Malignancies

Chairs: Brian Jonas (UC Davis) and Alex Herrera (City of Hope)

- 1:55 pm** New Developments in Acute Leukemia
Kevin Kelly, USC
- 2:15 pm** Question-and-Answer Session
- 2:20 pm** Multiple Myeloma: Current and Future Directions
Aaron Rosenberg, UC Davis
- 2:40 pm** Question-and-Answer Session
- 2:45 pm** Chronic Lymphocytic Leukemia: Updates
Tanya Siddiqi, City of Hope
- 3:05 pm** Question and Answer Session
- 3:10 – 3:25 pm** Refreshment break, Visit Exhibits

Session 7: Genitourinary Malignancies

Chairs: Primo Lara (UC Davis) and Sarmad Sadeghi (USC)

- 3:25 pm** Castration Resistant Prostate Cancer Therapy
Tanya Dorff, USC
- 3:45 pm** Question-and-Answer Session
- 3:50 pm** Updates in Renal Cell Carcinoma Drug Development
Sarmad Sadeghi, USC
- 4:10 pm** Question-and-Answer Session
- 4:15 pm** Bladder Cancer: Chemotherapy and Beyond!
Sandya Srinivas, Stanford
- 4:35 pm** Question and Answer Session

Session 8: Gynecologic Cancer

Chair: Oliver Dorigo, Stanford

- 4:40 pm** Management of Ovarian Cancer in 2016
Robert Morgan, City of Hope
- 5:00 pm** Question-and-Answer Session
- 5:05 pm** New Approaches to Cervix and Endometrial Cancer
Mihaela Cristea, City of Hope
- 5:25 pm** Question-and-Answer Session
- 5:30 pm** Post-session Survey

CONFERENCE AGENDA

SUNDAY, AUGUST 14th, 2016

7:00 am	Registration, Refreshments & Visit Exhibits
7:15 am – 8:15 am	Breakfast & Learn Symposia (non cme)
8:15 am	Introduction
8:20 am	Pre-session Survey

Session 9: Breast Cancer

Chair: Tianhong Li (UC Davis)

8:25 am	Hormone Receptor Positive Breast Cancer: What's New? <i>Helen Chew, UC Davis</i>
8:45 am	Question-and-Answer Session
8:50 am	Triple Negative Breast Cancer: Emerging Strategies <i>George Sledge, Stanford</i>
9:10 am	Question-and-Answer Session

Session 10: Rapid Review of Emerging and New Developments in Specific Tumor Types

Chairs: Warren Chow (City of Hope) and Przemyslaw Twardowski (City of Hope)

9:15 am	Malignant Melanoma and other Cutaneous Tumors <i>Emanuel Maverakis, UC Davis</i>
9:30 am	Question-and-Answer Session
9:35 am	Malignant Lymphomas <i>Joseph Tuscano, UC Davis</i>
9:50 am	Question-and-Answer Session
9:55 am	Soft Tissue Sarcomas <i>James Hu, USC</i>
10:10 am	Question-and-Answer Session
10:15 am	Head and Neck Cancer <i>A. Dimitrios Colevas, Stanford</i>
10:30 am	Question-and-Answer Session
10:35-10:50 am	Refreshment Break & Visit Exhibits

Session 11: Rapid Review of Emerging Therapeutic Strategies in Oncology

Chairs: Tim Synold (City of Hope) and Edward Newman (City of Hope)

10:50 am	Targeting DNA Damage Repair (PARP, ATR inhibitors) <i>Shivaani Kummar, Stanford</i>
11:05 am	Question-and-Answer Session
11:10 am	Targeting Heat Shock Proteins <i>Jonathan Riess, UC Davis</i>
11:25 am	Question-and-Answer Session
11:30 am	Newer Cytotoxics (e.g., eribulin, nab-paclitaxel) <i>David Quinn, USC</i>
11:45 am	Question-and-Answer Session
11:50 am	Chronic Myeloid Leukemia: Overcoming Resistance with New Agents <i>Mehrdad Abedi, UC Davis</i>
12:05 pm	Question-and-Answer Session
12:10 pm	Micro-RNAs in Oncology <i>Guido Marcucci, City of Hope</i>
12:25 pm	Question-and-Answer Session
12:30 pm	Post-session Survey
12:35 pm	Closing and Adjourn

HOTEL INFORMATION



THE WESTIN PASADENA

191 N Los Robles Avenue
Pasadena, CA 91101

**Reservations: 1-800-WESTIN
1-800-937-8461**

The Westin Pasadena welcomes guests with a full complement of facilities and amenities, all designed to ensure you leave feeling better than when you arrived. We prioritize convenience and simplicity with our 24-hour Business Center,

where you can put tasks behind you with ease, as well as Concierge services, for professional guidance on enjoying the best Pasadena has to offer. For reenergizing and clearing your mind, take advantage of our light-filled WestinWORKOUT® Fitness Studio and our alluring outdoor heated pool, with gorgeous views.

Enjoy some of the finest views of the San Gabriel Mountains and the Pasadena area from The Westin Pasadena, or step out to partake in the colorful spirit of downtown. Shoppers and food-lovers alike will revel in the remarkable range of options surrounding us. Just a few minutes on foot from the hotel, the Paseo Colorado features premier dining and retail outlets plus a cinema. Less than a mile away, historic Old Pasadena's charming storefronts house 200 shops plus a wide array of restaurants and night spots.

The Westin is located within walking distance of the Pacific Asia Museum areas, while the California Technical Institute, the historic Tournament of Roses house, and the Norton Simon Museum are all less than two miles away. A ten-minute drive will take you to the resplendent Huntington Library, with its extensive art collections and botanical gardens.

Golf enthusiasts will enjoy the 36-hole, William P. Bell-designed Brookside Golf Club, just a five-minute drive away. The nine-hole Eaton Canyon course is 15 minutes away in the San Gabriel foothills, and Santa Anita Park—a famous thoroughbred racetrack—is equally close by. The Rose Bowl, a world-famous sports and entertainment venue boasting beautiful greenery and cliff sides, is only five minutes away by car.

The Westin Pasadena is offering special rates during this conference of \$185 single or double room plus tax, European Plan (no meals). The cutoff date to make reservations is July 11th, 2016, after this date reservations are subject to hotel availability.

Make your hotel reservations by calling 1-800.937.8461 and use group code ***"12th Annual Cancer Consortium"***

CONFERENCE MANAGEMENT

MEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)

6619 South Dixie Highway, #341

Miami, FL 33143

Telephone: 305.663.1628

Fax: 305.675.2718

Website: www.meccinc.com

Email: tvalls@meccinc.com

Register online at www.meccinc.com under upcoming events.

12th Annual California Cancer Consortium Conference

“Recent Advances and New Directions in Cancer Therapy”

August 12-14, 2016, The Westin Pasadena, Pasadena, CA

Register online at www.meccinc.com or fax to 305.675.2718

Registration Form

Name _____ Degree _____

Address _____

Telephone (____) _____ Fax (____) _____


Email Address _____

Specialty _____

TYPE OF PRACTICE:

- Private Academic
 Hospital Other

REGISTRATION FEE:

- \$150 Physician
 \$ 75 Nurse, Nurse Practitioner, Resident, Fellow,
Students, Non-physician researchers and staff
(e.g., CRAs)
 \$250 Industry Professional
 \$ 50 Optional Fee for Maintenance of Certification
Credits 

MOC Requirements

ABIM ID# _____ (6 digits)

Date of Birth MM/DD _____

Refunds must be provided in writing prior to July 8th, 2016. A \$50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

Enclosed is my check i/a/of \$_____ for the registration of this conference.

I authorize MECC to charge my credit card i/a/o \$_____ for the registration of this course using the following credit card.

Name as it appears on the card _____ Exp. Date _____

Card number _____ CVV Code: _____

Authorized signature _____

**For those requiring special assistance, contact MECC
at 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2016**

Meetings, Events and Conference Coordinators, Inc.
P.O. Box 430376
Miami, FL 33243-0376

PRST STD
US Postage
PAID
Miami, FL
Permit No. 1429

12th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE
“Recent Advances and New Directions in Cancer Therapy”

August 12-14, 2016

The Westin Pasadena, Pasadena, CA